Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles

Sowers, MaryFran; McConnell, Daniel S.; Gast, Katherine M.; Zheng, Huiyong; Nan, Bin; McCarthy, Jenifer D.; Randolph, John F.

doi:10.1016/j.fertnstert.2009.07.1674

Cited by 128 publications

(98 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, it has been suggested that variation in AMH levels during the normal menstrual cycle and during OC-use is most pronounced in young women. This might also account for the obvious differences between the current study and previous reports (13).…”

Section: Discussioncontrasting

confidence: 91%

See 1 more Smart Citation

Influence of preterm birth and small birth size on serum anti-Müllerian hormone levels in young adult women

Kerkhof

Leunissen

Willemsen

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

Background/objectives: Preterm birth has been associated with reduced reproduction rates, and controversies remain regarding the effect of being born small for gestational age (SGA) on ovarian function. Recent findings in young men showed no effect of preterm and SGA birth on testis function. We hypothesised that follicle pool size in young adult women is also not affected by preterm and SGA birth. Design/methods: In 279 young women of the PROGRAM/PREMS study, aged 18-24 years, the influence of gestational age, birth length and birth weight on serum levels of anti-Mü llerian hormone (AMH) was analysed with multiple regression modelling. Additionally, AMH levels were analysed in preterm-versus term-born females and in three subgroups: females born SGA with either short stature or catch-up growth (SGA-CU), and females born term and appropriate for gestational age with normal stature (AGA controls). Results: Preterm and SGA birth did not affect AMH and other hormone levels. Older age at menarche and oral contraceptive pill use (OC-use) were related to lower AMH levels, and maternal smoking during gestation was related to higher AMH levels. After correction for maternal smoking, lower socioeconomic status (SES) was associated with lower AMH levels. In subgroup comparisons, SGA-CU women showed higher AMH levels than AGA controls, also after adjustment for several factors. Conclusion: Preterm and SGA birth did not affect AMH levels. Factors associated with serum AMH levels were OC-use, age at menarche, maternal smoking during gestation and SES. We conclude that preterm-and/or SGA-born females are not likely to have a reduced follicle pool size.

show abstract

Section: Discussioncontrasting

confidence: 91%

“…It is a marker of the follicle pool size, which decreases with age and is undetectable after menopause (8,9). Most studies showed that AMH levels are independent of menstrual cycle (10)(11)(12), but controversies still exist (13).…”

Section: Introductionmentioning

confidence: 99%

Influence of preterm birth and small birth size on serum anti-Müllerian hormone levels in young adult women

Kerkhof

Leunissen

Willemsen

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Indeed, AMH levels are stable across the menstrual cycle and are not affected by pregnancy or treatment with gonadotropinreleasing hormone agonists. In addition, although an effect of combined oral contraceptive pill on ovarian reserve has been described (Bentzen et al 2012, Deb et al 2012, Kallio et al 2013, its use seems to be associated with minimal suppression of the later FSH-dependent stages of follicle development (Arbo et al 2007, Streuli et al 2008, Sowers et al 2010, Li et al 2011, Shaw et al 2011. It is still debated if clinical and behavioral variables, such as BMI and smoking habit, may influence AMH plasma levels.…”

Section: Amh and Fertilitymentioning

confidence: 99%

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Bozza¹,

Puglisi²,

Lambertini³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Breast cancer is the most common invasive cancer in women of reproductive age. In young women, chemotherapy may induce amenorrhea: it is still uncertain how to assess menopausal status in these patients despite the importance of its definition for choosing appropriate endocrine treatment. In the development of sensitive biomarkers for fertility and ovarian reserve, anti-Mü llerian hormone (AMH) is considered a promising marker of ovarian reserve. The clearest data regarding a clinical use of AMH are related to the measurement of the ovarian pool in women who undergo IVF: the available data, also in breast cancer patients, seem to suggest that AMH measurement, before gonadotropin administration, can be a useful marker for the prediction of women at risk for poor-response or no response to ovarian stimulation. The utility of AMH as a potential marker of chemotherapy-induced ovarian follicular depletion and an early plasma marker of chemotherapy-induced gonadal damage has been evaluated both in young women after treatment for cancer in childhood and in young survivors of hematological malignancies and solid tumors. Several studies have demonstrated a potential utility of AMH, inhibin, or follicle-stimulating factor as biomarkers predicting infertility risk in breast cancer patients, but the studies conducted so far are not conclusive. Further studies are needed in order to define the regimen-specific action of chemotherapy on AMH levels, the percentage of post-treatment recovery of plasma levels of the hormone, and the relationship between menopausal status and AMH.

show abstract

“…AMH is strongly correlated with the antral follicle count and is relatively constant during and between menstrual cycles, in contrast to FSH (Hehenkamp et al, 2006;La Marca et al, 2006;Tsepelidis et al, 2007;Streuli et al, 2008). Although some studies did report variations during the cycle (Wunder et al, 2008;Streuli et al, 2009;Sowers et al, 2010;Robertson et al, 2011), the differences were small in amplitude and similar to the reported minor variability between cycles, which suggests that AMH production is independent of gonadotrophins. Therefore, AMH is a useful serum marker for the ovarian reserve.…”

Section: Discussionmentioning

confidence: 83%

Genetic variation may modify ovarian reserve in female childhood cancer survivors

Dorp¹,

Heuvel‐Eibrink²,

Stolk³

et al. 2013

Human Reproduction

View full text Add to dashboard Cite

study question: Are genetic polymorphisms, previously identified as being associated with age at menopause in the healthy population, associated with ovarian reserve and predicted age at menopause in adult long-term survivors of childhood cancer?summary answer: The CT genotype of rs1172822 in the BRSK1 gene is associated with lower serum anti-Müllerian hormone (AMH) levels and a younger predicted age at menopause in adult survivors of childhood cancer.what is known already: Gonadotoxicity is a well-known late side effect of chemotherapy and radiotherapy in adult survivors of childhood cancer. In the healthy population, several genetic polymorphisms are associated with age at natural menopause. Currently, data on the impact of previously identified variants in gene loci associated with ovarian reserve in adult long-term survivors of childhood cancer are lacking. study design, size, duration: We performed a pilot study in a single-centre cohort of adult female Caucasian childhood cancer survivors (n ¼ 176).participants/materials, setting, methods: We determined serum AMH levels (a marker of ovarian reserve) in adult survivors of childhood cancer (n ¼ 176) and studied single nucleotide polymorphisms (SNPs) previously reported to be associated with age at natural menopause: BRSK1 (rs1172822), ARHGEF7 (rs7333181), MCM8 (rs236114), PCSK1 (rs271924), IGF2R (rs9457827) and TNF (rs909253). Association analysis was performed using the additive genetic model. Linear regression was conducted to assess the effect of significant polymorphisms in two previously published menopause prediction models.main results and the role of chance: The CT genotype of rs1172822 in the BRSK1 (BR serine/threonine kinase 1) gene was negatively associated with serum AMH levels in our cohort (odds ratio: 3.15, 95% confidence interval: 1.35 -7.32, P ¼ 0.008) and significantly associated with the predicted age at menopause (P ¼ 0.04). The other five SNPs were not associated with serum AMH levels.limitations, reasons for caution: This is a pilot study showing preliminary data which must be confirmed. To confirm our findings and enlarge the project, a nationwide genome-wide association (GWA) project on the ovarian reserve in female survivors of childhood cancer should be performed, including a replication cohort.wider implications of the findings: Our findings support the hypothesis that previously identified genetic polymorphisms associated with age at menopause in healthy women may have an effect on the onset of menopause in female survivors of childhood cancer. Our study highlights a new aspect of the influences on the ovarian reserve after childhood cancer, which should be investigated further in a nationwide GWA study. Eventually, this information can help us to improve counselling on fertility preservation prior to cancer treatment based on genetic factors in individual patients.

show abstract

Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles

Cited by 128 publications

References 19 publications

Influence of preterm birth and small birth size on serum anti-Müllerian hormone levels in young adult women

Influence of preterm birth and small birth size on serum anti-Müllerian hormone levels in young adult women

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Genetic variation may modify ovarian reserve in female childhood cancer survivors

Contact Info

Product

Resources

About